Praxis Precision Medicines, Inc. (NASDAQ:PRAX) reported a wider-than-expected loss for the fourth quarter on Thursday.
The company posted quarterly losses of $3.50 per share which missed the analyst consensus estimate of losses of $3.08 per share.
“After a landmark fourth quarter, filled with a breadth of clinical and regulatory advancements across our portfolio, we started 2026 with two NDA submissions for ulixacaltamide and relutrigine. Pending their expected positive reviews, we will be positioned to transition into a commercial company,” said Marcio Souza, president and chief executive officer. “The other two programs in the clinic, vormatrigine and elsunersen, will both have topline results in the first half of 2026, keeping us on track for additional NDA submissions in the next two years. Together, these four assets have a revenue potential of over $20 billion.”
Praxis Precision Medicine shares fell 0.1% to trade at $303.00 on Friday.
These analysts made changes to their price targets on Praxis Precision Medicine following earnings announcement.
- Wedbush analyst Laura Chico maintained Praxis Precision Medicine with an Underperform rating and raised the price target from $95 to $130.
- Truist Securities analyst Joon Lee maintained the stock with a Buy and raised the price target from $500 to $700.
- Baird analyst Joel Beatty maintained Praxis Precision Medicine with an Outperform rating and raised the price target from $275 to $433.
Considering buying PRAX stock? Here’s what analysts think:
Photo via Shutterstock